心臓病学における人工知能市場の2030年までの予測：コンポーネント別、用途別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、心臓病学における人工知能の世界市場は2023年に7億4,408万米ドルを占め、2030年には7億4,661万米ドルに達すると予測され、予測期間中のCAGRは36.1%で成長する見込みです。

心臓病学における人工知能（AI）とは、心臓に関連する医療データを分析するための機械学習アルゴリズムと計算モデルの応用を指します。この技術は、心臓疾患の診断、モニタリング、治療方法の変革に大きな可能性を示しています。AIアルゴリズムは心エコー図の解釈を支援し、自動測定や異常の特定を行うことができます。AIモデルは、年齢、病歴、ライフスタイルなどの要因に基づいて、患者の心血管疾患発症リスクを評価することができます。AIを搭載したシステムは、ウェアラブルデバイスを通じて心臓疾患のある患者を継続的に監視し、気になる変化があればヘルスケアプロバイダーにリアルタイムでアラートを提供することができます。

2022年に米国国立生物工学情報センター（NCBI）が発表した最近の研究によると、AIアルゴリズムは95.4％の精度で不整脈を分類しました。さらにAIは、特異度94.52％、陽性適中率89.74％、陰性適中率98.55％、感度97.19％で病気を分類しました。この調査の研究者たちは、AIの使用により偽陽性が98.0％減少すると結論づけた。

心血管疾患の増加

心血管疾患の有病率は世界規模で上昇しています。その結果、診断と治療を支援するAIのような最先端のツールに対する需要が高まっています。AIを活用した診断技術は、心臓の不整脈をより早く発見し、迅速な治療を可能にし、おそらく病気の将来の進行を食い止めることができます。心血管疾患患者は、AIによって可能になるより正確な診断と治療戦略から恩恵を受ける可能性があります。循環器関連技術や進歩に対する規制当局の関心が高まるのは、循環器疾患の頻度が高まっているためかもしれないです。これにより、AIソリューションの創出と利用を促進する環境が醸成される可能性があります。

複雑な薬事承認と認証

AIを利用した医療機器やアプリケーションの規制当局による承認取得は、長く複雑なプロセスになる可能性があります。企業は規制機関に対し、AIソリューションの安全性、有効性、臨床的妥当性を証明しなければならないです。AIアプリケーションは、医療行為における倫理的ガイドラインを遵守しなければならないです。さらに、AIのアルゴリズムが公正であり、人種、性別、その他の人口統計学的要因に基づく偏りが生じないことを保証することは、規制上の重大な懸念事項として機能します。

電子カルテ（EHR）の採用拡大

病歴、診断検査、治療計画、処方箋など、整理された、あるいは非構造化されたさまざまな患者データは、電子カルテ（EHR）を通じて入手できます。AIアルゴリズムは、EHRを利用することで、手作業で分析するよりもはるかに多くの患者集団のデータを分析することができます。そのため、心臓の問題について、より強力で統計的に有意な洞察を得ることが可能になり、その結果、より正確な診断や治療法の提案が可能になるかもしれないです。AIはまた、EHRのデータ入力ミスを減らし、患者記録の精度と完全性を高めるのに役立つかもしれないです。したがって、循環器内科におけるEHRとAIの統合は市場の成長を促進します。

限定的な汎化

AIシステムが効果的に汎化できない場合、重要な心臓疾患の特定に失敗したり、偽陽性/陰性のフラグを立てたりする可能性があり、誤った医療判断につながる可能性があります。それは患者に不利な転帰をもたらし、法的・倫理的な影響を及ぼす可能性があります。ヘルスケア専門家は、AIシステムが一貫して不正確または信頼できない結果を提供する場合、AIシステムに対する信頼を失う可能性があります。そのため、臨床現場での採用や受容が妨げられる可能性があります。

COVID-19の影響

COVID-19の大流行は、ヘルスケアと心臓病学におけるAIの導入に直接的・間接的な影響を与えました。戸締まりや社会的距離を置く措置により、遠隔医療や遠隔監視ソリューションの需要が急増しました。循環器科を含むAI搭載ツールは、仮想診察や患者の心臓状態の遠隔監視を促進する上で重要な役割を果たしました。AIアルゴリズムは、COVID-19症例の診断とトリアージを支援するために迅速に導入されました。対面でのやり取りを最小限に抑える必要性から、遠隔画像診断への注目が高まり、AIが画像の解釈や心臓疾患の診断支援において重要な役割を果たすようになっています。

予測期間中、ソフトウェア分野が最大となる見込み

AIを活用した診断ソリューションのニーズが高まっていることから、ソフトウェア分野は有利な成長を遂げると推定されます。データ分析を通じて、AIベースのソフトウェアは医療上の意思決定を改善します。AIアルゴリズムによって支援されるECGは、患者の診断にかかる時間を短縮し、異常を特定することができます。さらに、このソフトウェアは生産性を向上させ、より優れた心臓分析を提供します。これらの要因が、心臓病学におけるAIソフトウェアの需要を向上させています。

予測期間中、心臓不整脈分野のCAGRが最も高くなる見込み

心臓不整脈セグメントは、予測期間中に最も高いCAGR成長が見込まれます。AIアルゴリズムは心電図（ECG）を解析して、心房細動、心室頻拍、徐脈などのさまざまなタイプの不整脈を特定・分類できます。AIアルゴリズムは、ホルターモニターによって収集された長期のECGデータを処理することができます。不整脈のエピソードを特定・記録し、ヘルスケア・プロバイダーが後で確認できるようにすることができます。加えて、個別化された治療計画、遠隔医療、ECG解釈支援は、このセグメントの成長を後押ししています。

最大のシェアを占める地域

北米は、確立されたヘルスケアインフラ、技術的に先進的な製品の急速な採用、AI製品の規制承認の増加により、予測期間中最大の市場シェアを占めると予測されます。北米、特に米国は技術革新と開発の中心地です。また、この地域はAIアプリケーションを含むヘルスケア技術に多額の投資を集めています。さらに、遠隔医療が重視されるようになり、患者中心のケアへの関心が高まっていることも、市場の需要を後押ししています。

CAGRが最も高い地域：

アジア太平洋地域は、高齢者人口の増加、ヘルスケアインフラの発展、地域の経済状況の改善により、予測期間中のCAGRが最も高くなると予測されています。さらに、この地域では心血管疾患の有病率が高いです。中国はCVD患者の記録でトップに位置しています。したがって、この地域の高い疾病負担と発展途上の医療インフラは、心臓の診断と治療におけるAIの採用を改善すると予想されます。

無料のカスタマイズ提供：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• アプリケーション分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 心臓病市場における世界の人工知能：コンポーネント別

• ソフトウェア
• ハードウェア
• サービス

第6章 心臓病学市場における世界の人工知能：アプリケーション別

• 脳卒中
• 心不整脈
• 虚血性心疾患
• その他の用途

第7章 循環器市場における世界の人工知能：エンドユーザー別

• ヘルスケア支払者
• ライフサイエンス企業
• ヘルスケア提供者

第8章 心臓病学市場における世界の人工知能：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Arterys Inc.
• IDOVEN
• Cardiologs
• Ultrasight
• Ultromics Limited
• DiA Imaging Analysis
• CardiAI
• Viz AI
• Cleerly, Inc
• RSIP Vision
• Vista AI
• HeartVista Inc
• Caption Health
• HeartFlow
• Bay Labs
• Siemens Healthineers
• NuvoAir
• PathAI

List of Tables

• Table 1 Global Artificial Intelligence In Cardiology Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
• Table 3 Global Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
• Table 4 Global Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
• Table 5 Global Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
• Table 6 Global Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
• Table 7 Global Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
• Table 8 Global Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
• Table 9 Global Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
• Table 10 Global Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 11 Global Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
• Table 12 Global Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
• Table 13 Global Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
• Table 14 Global Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
• Table 15 North America Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
• Table 16 North America Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
• Table 17 North America Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
• Table 18 North America Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
• Table 19 North America Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
• Table 20 North America Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
• Table 21 North America Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
• Table 22 North America Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
• Table 23 North America Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
• Table 24 North America Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 25 North America Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
• Table 26 North America Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
• Table 27 North America Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
• Table 28 North America Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
• Table 29 Europe Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
• Table 30 Europe Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
• Table 31 Europe Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
• Table 32 Europe Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
• Table 33 Europe Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
• Table 34 Europe Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
• Table 35 Europe Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
• Table 36 Europe Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
• Table 37 Europe Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
• Table 38 Europe Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 39 Europe Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
• Table 40 Europe Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
• Table 41 Europe Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
• Table 42 Europe Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
• Table 43 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
• Table 44 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
• Table 45 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
• Table 46 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
• Table 47 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
• Table 48 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
• Table 49 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
• Table 50 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
• Table 51 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
• Table 52 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 53 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
• Table 54 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
• Table 55 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
• Table 56 Asia Pacific Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
• Table 57 South America Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
• Table 58 South America Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
• Table 59 South America Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
• Table 60 South America Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
• Table 61 South America Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
• Table 62 South America Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
• Table 63 South America Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
• Table 64 South America Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
• Table 65 South America Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
• Table 66 South America Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 67 South America Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
• Table 68 South America Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
• Table 69 South America Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
• Table 70 South America Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)
• Table 71 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Country (2021-2030) ($MN)
• Table 72 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Component (2021-2030) ($MN)
• Table 73 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Software (2021-2030) ($MN)
• Table 74 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Hardware (2021-2030) ($MN)
• Table 75 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Services (2021-2030) ($MN)
• Table 76 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Application (2021-2030) ($MN)
• Table 77 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Stroke (2021-2030) ($MN)
• Table 78 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Cardiac Arrhythmias (2021-2030) ($MN)
• Table 79 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Ischemic Heart Disease (2021-2030) ($MN)
• Table 80 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 81 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By End User (2021-2030) ($MN)
• Table 82 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Healthcare Payers (2021-2030) ($MN)
• Table 83 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Life Science Companies (2021-2030) ($MN)
• Table 84 Middle East & Africa Artificial Intelligence In Cardiology Market Outlook, By Healthcare Providers (2021-2030) ($MN)

According to Stratistics MRC, the Global Artificial Intelligence in Cardiology Market is accounted for $744.08 million in 2023 and is expected to reach $746.61 million by 2030 growing at a CAGR of 36.1% during the forecast period. Artificial Intelligence (AI) in cardiology refers to the application of machine learning algorithms and computational models to analyze medical data related to the heart. This technology has shown tremendous promise in transforming the way cardiac conditions are diagnosed, monitored, and treated. AI algorithms can assist in the interpretation of echocardiograms, providing automated measurements and identifying abnormalities. AI models can assess a patient's risk of developing cardiovascular diseases based on factors like age, medical history, and lifestyle. AI-powered systems can continuously monitor patients with heart conditions through wearable devices, providing real-time alerts to healthcare providers for any concerning changes.

According to a recent study published by the National Center for Biotechnology Information (NCBI) in 2022, an AI algorithm classified arrhythmia with 95.4% accuracy. Furthermore, AI classified the disease with a specificity of 94.52%, positive predictive value of 89.74%, negative predictive value of 98.55%, and 97.19% sensitivity. The researchers of the study concluded that AI's use would reduce the overall false-positive results by 98.0%.

Market Dynamics:

Driver:

Rising cardiovascular disease rates

The prevalence of cardiovascular ailments is rising on a global scale. As a result, there is an increasing demand for cutting-edge tools like AI to aid in diagnosis and treatment. AI-powered diagnostic technologies can spot cardiac irregularities sooner, enabling prompt treatment and perhaps halting the disease's future progression. Cardiovascular disease patients may benefit from more precise diagnosis and treatment strategies made possible by AI. Increased regulatory attention to cardiology-related technologies and advances may result from the growing frequency of cardiovascular disorders. This may foster an environment that encourages the creation and use of AI solutions.

Restraint:

Complex regulatory approval and certification

Obtaining regulatory approval for AI-based medical devices or applications can be a lengthy and complex process. Companies must demonstrate the safety, efficacy, and clinical validity of their AI solutions to regulatory bodies. AI applications must adhere to ethical guidelines in medical practice. Further, ensuring that AI algorithms are fair and do not introduce biases based on race, gender, or other demographic factors acts as a significant regulatory concern.

Opportunity:

Increasing adoption of Electronic Health Records (EHRs)

A variety of organised and unstructured patient data, including as medical histories, diagnostic tests, treatment plans, prescriptions, and more, is available through electronic health records (EHRs). AI algorithms can analyse data from a far wider patient population using EHRs than they could manually. This makes it possible to get stronger and statistically significant insights into heart problems, which may result in more precise diagnosis and therapy suggestions. AI may also aid in reducing data input mistakes in EHRs and enhancing the precision and thoroughness of patient records. Therefore, the integration of AI with EHRs in cardiology fuels the growth of the market.

Threat:

Limited generalization

If the AI system is not able to generalize effectively, it may fail to identify important cardiac conditions or may flag false positives/negatives, potentially leading to incorrect medical decisions. It leads to adverse patient outcomes and there could be legal and ethical implications. Healthcare professionals may lose confidence in the AI system if it consistently provides inaccurate or unreliable results. This can hinder its adoption and acceptance in clinical practice.

COVID-19 Impact

The COVID-19 pandemic has had both direct and indirect impacts on healthcare and the adoption of AI in cardiology. Due to lockdowns and social distancing measures, there was a surge in demand for telemedicine and remote monitoring solutions. AI-powered tools, including those in cardiology, played a significant role in facilitating virtual consultations and remote monitoring of patients' cardiac conditions. AI algorithms were swiftly deployed to assist in the diagnosis and triage of COVID-19 cases. The need for minimizing in-person interactions led to an increased focus on remote diagnostic imaging, where AI can play a crucial role in interpreting images and aiding in the diagnosis of cardiac conditions.

The software segment is expected to be the largest during the forecast period

The software segment is estimated to have a lucrative growth, due to the growing need for AI-enabled diagnostic solutions. Through data analysis, AI-based software improves medical decision-making. The ECG, aided by AI algorithms, has shortened the time it takes to diagnose patients and is capable of identifying anomalies. Moreover, this software increases productivity and provides better heart analysis. These factors are improving the demand for AI software in cardiology.

The cardiac arrhythmias segment is expected to have the highest CAGR during the forecast period

The cardiac arrhythmias segment is anticipated to witness the highest CAGR growth during the forecast period. AI algorithms can analyze electrocardiograms (ECGs) to identify and classify various types of arrhythmias, including atrial fibrillation, ventricular tachycardia, and bradycardia. AI algorithms can process long-term ECG data collected by Holter monitors. They can identify and record episodes of arrhythmias for later review by healthcare providers. In addition, personalized treatment planning, telemedicine and ECG interpretation assistance are boosting the segment growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its well-established healthcare infrastructure, rapid adoption of technologically advanced products, and increased regulatory approvals of AI products. North America, particularly the United States, is a hub for technological innovation and development. Also, the region attracts significant investment in healthcare technology, including AI applications. Moreover, the growing emphasis on telemedicine and growing focus on patient-centric care is propelling the market demand.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the growing geriatric population, developing healthcare infrastructure, and improvement in the region's economic conditions. Moreover, there is a high prevalence of cardiovascular diseases in the region. China is positioned in top for CVD patient's records. Therefore, the region's high disease burden and developing healthcare infrastructure are expected to improve the adoption of AI in cardiac diagnosis and treatment.

Key players in the market:

Some of the key players profiled in the Artificial Intelligence In Cardiology Market include: Arterys Inc., IDOVEN, Cardiologs, Ultrasight, Ultromics Limited, DiA Imaging Analysis, CardiAI, Viz AI, Cleerly, Inc, RSIP Vision, Vista AI, HeartVista Inc, Caption Health, HeartFlow, Bay Labs, Siemens Healthineers, NuvoAir and PathAI.

Key Developments:

In August 2023, Siemens Healthineers unveils the Acuson Origin1, a dedicated cardiovascular ultrasound system with new, robust artificial intelligence (AI) features. Designed to improve patient outcomes and help physicians perform minimally invasive cardiac procedures more efficiently, the Acuson Origin addresses the entire continuum of cardiovascular patient care, including diagnostic, structural heart, electrophysiological, and pediatric procedures.

In February 2023, DiA Imaging Analysis received U.S. FDA clearance for its LVivo IQS software solution, which is used to provide high-quality echocardiography images of the heart to physicians.

In April 2022, Arterys has launched Strain + AI a new cardio AI feature. Strain + AI has beautiful, easy to interpret color and vector overlays, 17-segment models, and plot curves and automatically provides strain and strain rate decomposed into radial and circumferential components as well as myocardial velocity.

Components Covered:

• Software
• Hardware
• Services

Applications Covered:

• Stroke
• Cardiac Arrhythmias
• Ischemic Heart Disease
• Other Applications

End Users Covered:

• Healthcare Payers
• Life Science Companies
• Healthcare Providers

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Artificial Intelligence In Cardiology Market, By Component

• 5.1 Introduction
• 5.2 Software
• 5.3 Hardware
• 5.4 Services

6 Global Artificial Intelligence In Cardiology Market, By Application

• 6.1 Introduction
• 6.2 Stroke
• 6.3 Cardiac Arrhythmias
• 6.4 Ischemic Heart Disease
• 6.5 Other Applications

7 Global Artificial Intelligence In Cardiology Market, By End User

• 7.1 Introduction
• 7.2 Healthcare Payers
• 7.3 Life Science Companies
• 7.4 Healthcare Providers

8 Global Artificial Intelligence In Cardiology Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Arterys Inc.
• 10.2 IDOVEN
• 10.3 Cardiologs
• 10.4 Ultrasight
• 10.5 Ultromics Limited
• 10.6 DiA Imaging Analysis
• 10.7 CardiAI
• 10.8 Viz AI
• 10.9 Cleerly, Inc
• 10.10 RSIP Vision
• 10.11 Vista AI
• 10.12 HeartVista Inc
• 10.13 Caption Health
• 10.14 HeartFlow
• 10.15 Bay Labs
• 10.16 Siemens Healthineers
• 10.17 NuvoAir
• 10.18 PathAI